Articles tagged with: Bortezomib
The results of a recent retrospective study suggest that treatment with Velcade or thalidomide may increase multiple myeloma patients’ risk of developing abnormal lung function.
Specifically, patients treated with Velcade (bortezomib)-based regimens were twice as likely to develop lung obstruction, and those treated with thalidomide (Thalomid)-based regimens were twice as likely to develop lung restriction.
However, the study investigators note that their study did not include information about lung disease patients may have had before their myeloma therapy. The researchers acknowledge that this could affect the interpretation of …
Myeloma Patients May Be At Higher Risk For Restless Legs Syndrome – Results from a recent Turkish study show that restless legs syndrome occurs more frequently in multiple myeloma patients than in healthy adults. Restless legs syndrome is a condition characterized by uncomfortable sensations in the legs and an uncontrollable urge to move them, often leading to sleep deprivation. In this study, 18 percent of myeloma patients had restless legs syndrome, compared to 3 percent in the healthy population. Multiple myeloma patients with restless legs syndrome had higher levels of depression and anxiety and a poorer quality of life compared to those without the condition. The researchers conclude that targeting restless legs syndrome may improve overall health outcomes in myeloma patients. For more information, please see the study in the Journal of Clinical Medicine Research (abstract).
Ibrutinib Enhances Anti-Myeloma Activity Of Velcade And Revlimid – Results from a recent preclinical study show that ibrutinib (PCI-32765) may enhance the activity of Velcade (bortezomib) plus Revlimid (lenalidomide). Ibrutinib, which is being developed by biotech company Pharmacyclics in cooperation with Johnson & Johnson, blocks a protein called Bruton’s tyrosine kinase (Btk). Btk is found in antibody-producing cells and in cells that break down bone tissue. Ibrutinib is currently being investigated as a potential treatment for a number of different blood cancers, including multiple myeloma. The study researchers believe their data warrants further investigation of ibrutinib as part of a combination drug therapy for multiple myeloma. For more information, please see the study in Cellular Signalling (abstract).
Phase 1/2 Clinical Trial To Study PRLX 93936 In Relapsed And Refractory Multiple Myeloma Patients – Prolexys Pharmaceuticals is starting a Phase 1/2 clinical trial of PRLX 93936 in relapsed and refractory myeloma patients. PRLX 93936 is a small-molecule anti-cancer treatment that targets the RAS protein. Specifically, researchers are seeking to determine patient response to and the maximum tolerated dose of PRLX 93936. Patients must have received two or more prior treatment regimens, including a proteasome inhibitor (such as Velcade) and/or an immunomodulatory agent (such as Revlimid) to be eligible for the study. For more information, please see the clinical trial description.
Results from a small, retrospective study indicate that combination therapy with Velcade, cyclophosphamide, and dexamethasone may be effective in newly diagnosed myeloma patients with kidney damage.
The findings, discussed in a letter to the editor of the European Journal of Haematology, show that kidney impairment did not worsen in any patients who received the three-drug treatment.
The study investigators also note that side effects were manageable, but recommend further research of the three-drug therapy to determine its safety as a long-term treatment option.
Kidney impairment is a common myeloma-related complication. …
Subcutaneous Velcade Receives Approval In Europe For Multiple Myeloma – Janssen-Cilag, the company that markets Velcade (bortezomib) in Europe, announced on Friday that the European Medicines Agency has granted marketing authorization of subcutaneous Velcade. The decision was based on results of a Phase 3 study demonstrating that subcutaneous Velcade is as effective as intravenous Velcade but associated with fewer and less serious side effects. Europe is the third region where subcutaneous Velcade is now available; both the U.S. Food and Drug Administration and Health Canada approved the use of subcutaneous Velcade for myeloma in their respective countries earlier this year. For more information, see the press release from Janssen-Cilag or the Phase 3 results published in the journal Hematologica (abstract).
Methyljasmonate Shows Activity Against Multiple Myeloma – Results from a recent preclinical study suggest that methyljasmonate, a compound produced by plants under stressful conditions, may be active against multiple myeloma. Previous studies have shown that a related family of plant compounds called jasmonates can kill various types of cancer cells. In the current study, researchers found that methyljasmonate was able to kill myeloma cells lines and myeloma cells from patient samples at concentrations that did not affect normal stem cells. In mice that carried diffuse multiple myeloma lesions, a combination of methyljasmonate and Velcade prolonged overall survival time more than either drug alone. For more information, please see the study in the British Journal of Hematology (abstract).
Phase 1/2 Clinical Trial To Study Rapamune-Hydroxychloroquine Combination In Relapsed And Refractory Myeloma Patients – The Knight Cancer Institute at the Oregon Health and Science University is starting a Phase 1 trial of Rapamune (sirolimus or rapamycin) and hydroxychloroquine (Plaquenil) in combination with cyclophosphamide (Cytoxan) and dexamethasone (Decadron) in relapsed and refractory multiple myeloma patients. Myeloma patients must have received at least one prior therapy to be able to participate in the trial. Rapamune belongs to the same class of drugs as Torisel (temsirolimus) and Afinitor (everolimus) called mTor inhibitors; it is currently approved for the prevention of kidney rejection. Hydroxychloroquine is used to prevent and treat malaria and to treat rheumatoid arthritis. Both agents have been studied in preclinical studies for multiple myeloma. For more information, please see the clinical trial description.
Donor Stem Cell Transplants May Be More Effective But Less Safe Than Autologous Transplants As Second Transplant For Myeloma Patients – Results from a recent retrospective analysis show that allogeneic (donor) stem cell transplants may be more effective but less safe than autologous (self) stem cell transplants in myeloma patients who have already received an autologous transplant. The analysis included data from 1,192 patients who received two autologous transplants and 630 patients who received one autologous transplant followed by a donor transplant. Patients in the auto/donor group received reduced-intensity chemotherapy after the autologous transplant, in preparation for the donor transplant. The results showed that patients in the auto/donor group were 1.4 times more likely than patients in the auto/auto group to achieve a complete response. However, auto/donor patients had a 3.3-fold higher risk of treatment-related death than auto/auto counterparts. Overall survival and progression-free survival were comparable between both groups of patients. For more information, please refer to the study in Bone Marrow Transplantation (abstract).
GF-15 May Prevent Myeloma Growth By Disrupting Cell Division – Results from a recent German preclinical study show that the compound GF–15 disrupts the division of myeloma cells and triggers their death. Specifically, GF–15 kills myeloma cells by preventing centrosomal clustering, a technique used by cancerous cells to divide correctly. The German researchers found that GF-15 was effective in 30 percent of bone marrow samples from relapsed myeloma patients. They also found that GF–15, in combination with melphalan (Alkeran), was significantly less toxic in mice than a GF-15 plus Velcade (bortezomib). The researchers conclude that their findings support further development of the drug in clinical trials. For more information, please see the study in Cancer Research (abstract).
Linsitinib May Help Overcome Velcade Resistance In Multiple Myeloma – A recent preclinical study found that the investigational treatment linsitinib (ASP7487, OSI-906), which is being developed Japanese pharmaceutical company Astellas Pharma, may help overcome Velcade resistance in multiple myeloma. Linsitinib is a protein that triggers cancer cell death by inhibiting insulin-like growth factor 1 (IGF-1). IGF-1 is found on the surface of human cells and has been linked to Velcade-resistance. Specifically, the researchers found that linsitinib acted synergistically with Velcade and killed 47 percent of Velcade-resistant myeloma cells. The investigators believe their findings provide a rationale for studying linsitinib together with Velcade in clinical trials. A Phase 1/2 trial of linsitinib in combination with Velcade and dexamethasone in relapsed and refractory multiple myeloma patients is starting at the University Health Network of Toronto (see related Beacon news). For more information, please see the study in the journal Blood (abstract).
Patrys To Start Phase 1/2 Trial Of PAT-SM6 In Relapsed/Refractory Myeloma – The Australian biopharmaceutical company Patrys announced last week that it will be starting a Phase 1/2 trial of its investigational drug PAT-SM6 in relapsed and refractory multiple myeloma patients in Germany. PAT-SM6 is a human antibody that has shown promising activity in preclinical studies in a variety of cancers, including melanoma, breast, colon and pancreatic cancer as well as multiple myeloma. The trial will start at the University Hospital of Wuerzbug, lead by myeloma expert Professor Herman Einsele. For more information, please the Patrys press release.